(Q50583865)

16 March 2018

title

Interferon alpha and ribavirin for membranoproliferative glomerulonephritis and hepatitis C infection. (English)

1 reference

16 March 2018

membranoproliferative glomerulonephritis

1 reference

1 reference

1 reference

6

1 reference

16 March 2018

François Paraf

object named as

François Paraf

5

0 references

author name string

Véronique Loustaud-Ratti

1

1 reference

16 March 2018

Eric Liozon

2

1 reference

16 March 2018

Hussein Karaaslan

3

1 reference

16 March 2018

Sophie Alain

4

1 reference

16 March 2018

François Denis

7

1 reference

16 March 2018

Elisabeth Vidal

8

1 reference

16 March 2018

language of work or name

English

0 references

publication date

1 October 2002

1 reference

16 March 2018

American Journal of Medicine

published in

1 reference

16 March 2018

volume

113

1 reference

16 March 2018

issue

6

1 reference

16 March 2018

page(s)

516-519

1 reference

16 March 2018

Membranoproliferative glomerulonephritis associated with hepatitis C virus infection

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Hepatitis C virus-associated glomerulonephritis. Effect of alpha-interferon therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Successful treatment of HCV-associated cryoglobulinaemic glomerulonephritis with a combination of interferon-alpha and ribavirin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

A role for hepatitis C virus infection in type II cryoglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Hepatitis C virus and cryoglobulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Response to high-dose interferon-alpha after failure of standard therapy in MPGN associated with hepatitis C virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Ribavirin and immune thrombocytopenic purpura.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Inhibition of immune functions by antiviral drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

Prednisone withdrawal followed by interferon alpha for treatment of chronic hepatitis C infection: results of a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2802%2901257-3

10.1016/S0002-9343(02)01257-3

7 January 2021

Identifiers

DOI

1 reference

16 March 2018

PubMed ID

12427502

1 reference

16 March 2018